Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 4;10:395. doi: 10.3389/fcimb.2020.00395

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Alrubayyi, Ogbe, Moreno Cubero and Peppa.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Therapeutic startegies to harness NK cells in HIV infection. (A) NK cell activation strategies through broadly neutralizing antibodies (bNAbs), engineered proteins, Bi-specific or Tri-specific Killer engagers (BiKEs or TriKEs), soluble mediators such as cytokines and TLR agonists to boost NK effector functions including cytotoxicity and cytokine production. (B) Release of NK inhibition via engagement of monoclonal antibodies (mAb) directly against inhibitory receptors NKG2A and inhibitory Killer-cell immunoglobulin-like receptor (iKIRs). (C) CAR-engineered NK cells to target HIV infected cells. PBMC, peripheral blood mononuclear cells; HSPCs, hematopoietic stem/progenitor cells; iPSC, induced pluripotent stem cells; CB, cord blood.